JP2018523675A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523675A5
JP2018523675A5 JP2018507672A JP2018507672A JP2018523675A5 JP 2018523675 A5 JP2018523675 A5 JP 2018523675A5 JP 2018507672 A JP2018507672 A JP 2018507672A JP 2018507672 A JP2018507672 A JP 2018507672A JP 2018523675 A5 JP2018523675 A5 JP 2018523675A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
pharmaceutical formulation
streptococcus
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018507672A
Other languages
English (en)
Japanese (ja)
Other versions
JP6757402B2 (ja
JP2018523675A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/054890 external-priority patent/WO2017029602A2/en
Publication of JP2018523675A publication Critical patent/JP2018523675A/ja
Publication of JP2018523675A5 publication Critical patent/JP2018523675A5/ja
Application granted granted Critical
Publication of JP6757402B2 publication Critical patent/JP6757402B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018507672A 2015-08-16 2016-08-15 ピラジノ[2,3−b][1,4]オキサジン−3−オン又は関連する環系を含む抗菌剤 Expired - Fee Related JP6757402B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US62/205,732 2015-08-16
US201662308928P 2016-03-16 2016-03-16
US62/308,928 2016-03-16
PCT/IB2016/054890 WO2017029602A2 (en) 2015-08-16 2016-08-15 Compounds for use in antibacterial applications

Publications (3)

Publication Number Publication Date
JP2018523675A JP2018523675A (ja) 2018-08-23
JP2018523675A5 true JP2018523675A5 (cg-RX-API-DMAC10.html) 2019-09-26
JP6757402B2 JP6757402B2 (ja) 2020-09-16

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507672A Expired - Fee Related JP6757402B2 (ja) 2015-08-16 2016-08-15 ピラジノ[2,3−b][1,4]オキサジン−3−オン又は関連する環系を含む抗菌剤

Country Status (22)

Country Link
US (2) US10364254B2 (cg-RX-API-DMAC10.html)
EP (1) EP3334739A2 (cg-RX-API-DMAC10.html)
JP (1) JP6757402B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180038046A (cg-RX-API-DMAC10.html)
CN (1) CN108137616B (cg-RX-API-DMAC10.html)
AU (2) AU2016307969C1 (cg-RX-API-DMAC10.html)
CA (1) CA2995715A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018000403A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018002204A2 (cg-RX-API-DMAC10.html)
CR (1) CR20180111A (cg-RX-API-DMAC10.html)
DO (1) DOP2018000049A (cg-RX-API-DMAC10.html)
EA (1) EA033314B1 (cg-RX-API-DMAC10.html)
HK (1) HK1248680A1 (cg-RX-API-DMAC10.html)
IL (1) IL257265B (cg-RX-API-DMAC10.html)
MA (1) MA42621A (cg-RX-API-DMAC10.html)
MX (1) MX2018002033A (cg-RX-API-DMAC10.html)
PE (1) PE20181143A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018500358A1 (cg-RX-API-DMAC10.html)
TW (1) TW201722965A (cg-RX-API-DMAC10.html)
UY (1) UY36851A (cg-RX-API-DMAC10.html)
WO (1) WO2017029602A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201800722B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
TW202116782A (zh) 2019-07-16 2021-05-01 瑞士商愛杜西亞製藥有限公司 喹啉酮衍生物
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法
EP4493551A1 (en) 2022-03-14 2025-01-22 Slap Pharmaceuticals LLC Multicyclic compounds
WO2025132870A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Intellectual Property (No.4) Limited Chemical compounds and uses thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (cg-RX-API-DMAC10.html) * 1969-10-13 1971-09-23 Eisai Co Ltd
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
IE56059B1 (en) 1982-10-08 1991-04-10 Glaxo Group Ltd Devices for administering medicaments to patients
BE905189A (fr) 1985-07-30 1987-01-29 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients.
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
HU213221B (en) 1990-03-02 1997-03-28 Glaxo Group Ltd Inhalation device and medicine packet for device
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
DE60025048D1 (de) 2000-07-21 2006-01-26 Ljudmila Petrovna Maljuk Teller für stehempfänge
HUP0300721A3 (en) 2000-07-26 2006-02-28 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
WO2002050036A1 (en) 2000-12-21 2002-06-27 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
AR040335A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
EP1519938B1 (en) 2002-06-27 2007-04-11 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
BR0315221A (pt) 2002-10-10 2005-08-23 Morphochem Ag Komb Chemie Compostos com atividade antibacteriana
DE60331849D1 (de) 2002-11-05 2010-05-06 Glaxosmithkline Llc Antibakterielle wirkstoffe
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
KR101281775B1 (ko) 2003-12-19 2013-07-15 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된마이크로- 및 나노- 구조를 제작하는 방법
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
WO2007021762A2 (en) 2005-08-09 2007-02-22 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US20070254872A1 (en) 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
WO2006017326A1 (en) 2004-07-13 2006-02-16 Glaxo Group Limited Antibacterial agents
WO2006012396A1 (en) 2004-07-22 2006-02-02 Glaxo Group Limited Antibacterial agents
DE602005024151D1 (de) 2004-08-02 2010-11-25 Glaxo Group Ltd Antibakterielle mittel
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
ATE466857T1 (de) 2004-10-05 2010-05-15 Actelion Pharmaceuticals Ltd Neue piperidin-antibiotika
WO2006046552A1 (ja) 2004-10-27 2006-05-04 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
US7605169B2 (en) 2005-01-25 2009-10-20 Glaxo Group Limited Antibacterial agents
CN101258157A (zh) * 2005-05-24 2008-09-03 阿斯利康(瑞典)有限公司 具有抗菌活性的氨基哌啶喹啉及其氮杂等构类似物
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US8329694B2 (en) 2005-06-24 2012-12-11 Toyama Chemical Co., Ltd. Quinoxalinones as antibacterial composition
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
US8944804B2 (en) 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
JP5191053B2 (ja) * 2006-02-15 2013-04-24 アクテリオン ファーマシューティカルズ リミテッド エタノールまたは1,2−エタンジオールシクロヘキシル抗生物質誘導体
BRPI0712163A2 (pt) 2006-05-26 2012-03-13 Toyama Chemical Co., Ltd. composto, e, agente antimicrobiano
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
CL2007003693A1 (es) * 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
GB0707704D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
US7976759B2 (en) 2007-10-12 2011-07-12 Liquidia Technologies, Inc. System and method for producing particles and patterned films
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
CN104151316B (zh) * 2008-10-07 2016-06-15 埃科特莱茵药品有限公司 三环噁唑烷酮抗生素化合物
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
TW201022279A (en) * 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
US8444907B2 (en) 2008-12-05 2013-05-21 Liquidia Technologies, Inc. Method for producing patterned materials
MX2011005905A (es) * 2008-12-12 2011-06-20 Actelion Pharmaceuticals Ltd Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
JP5656996B2 (ja) 2009-07-13 2015-01-21 ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル 工学的に作製されたエアロゾル粒子、およびそれに関連した方法
JP5685589B2 (ja) * 2010-05-25 2015-03-18 大正製薬株式会社 新規な複素環化合物又はその塩
AU2012275499A1 (en) * 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
CA2854266A1 (en) * 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
PL2986607T3 (pl) 2013-04-16 2017-11-30 Idorsia Pharmaceuticals Ltd Przeciwbakteryjne pochodne biaromatyczne
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas

Similar Documents

Publication Publication Date Title
JP2018523675A5 (cg-RX-API-DMAC10.html)
CN114269746A (zh) 一种螺芳环化合物、其制备及应用
CN111683928A (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
MX2019003060A (es) Compuestos inhibidores de beta-lactamasa.
SA520411571B1 (ar) مركبات كرومان مونوباكتام لعلاج العدوى البكتيرية
HRP20190603T1 (hr) 2-supstituirani spojevi cefema
SA521431048B1 (ar) مركبات بيروليدين
RU2014143821A (ru) 1, 3, 4-ОКСАДИАЗОЛЬНЫЕ И 1, 3, 4-ТИАДИАЗОЛЬНЫЕ ИНГИБИТОРЫ β-ЛАКТАМАЗЫ
JP2014051497A5 (cg-RX-API-DMAC10.html)
TN2014000417A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
JP2018531941A5 (cg-RX-API-DMAC10.html)
JP2013532687A5 (cg-RX-API-DMAC10.html)
PH12017500852B1 (en) Combination therapy for treatment of resistant bacterial infections
JP2017517547A5 (cg-RX-API-DMAC10.html)
NZ740051A (en) Tetracycline compounds
EA201890694A1 (ru) Группа соединений, применяющихся для лечения или предупреждения гиперурикемии или подагры
NZ731966A (en) Novel imaging composition and uses thereof
JP2016505007A5 (cg-RX-API-DMAC10.html)
JP2020536966A5 (cg-RX-API-DMAC10.html)
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
WO2018109042A3 (en) Antimicrobial peptides
Dong et al. Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide
JP2019501896A5 (cg-RX-API-DMAC10.html)
EA201490436A1 (ru) Антибактериальные 3,4-дигидро-1н-[1,8]нафтиридиноны, замещенные гомопиперидинилом
EA201890412A1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ